Drug pipeline
Explore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Phospholipase A2 group IIA (PLA2G2A), commonly known as synovial phospholipase A2 or group IIA secretory phospholipase A2 (sPLA2-IIA), is a calcium-dependent secretory enzyme that plays a pivotal role in lipid metabolism, host defense, and the propagation of inflammatory pathways. Originally isolated from the synovial fluid of rheumatoid arthritis patients, PLA2G2A catalyzes the hydrolysis of the sn-2 ester bond of glycerophospholipids, releasing free fatty acids (such as arachidonic acid) and lysophospholipids. These products serve as precursors for the synthesis of potent pro-inflammatory eicosanoids, including prostaglandins and leukotrienes, which drive chronic inflammatory diseases like rheumatoid arthritis, asthma, and cardiovascular disorders. Beyond its catalytic activity, PLA2G2A acts as a ligand for integrins and other cell-surface receptors, triggering intracellular signaling cascades (such as EGFR/ERK pathways) that promote cell proliferation, migration, and tissue remodeling.
In clinical development, PLA2G2A has been targeted by small-molecule active-site inhibitors like varespladib and varespladib methyl, which were evaluated for inflammatory and cardiovascular indications. However, the Phase III VISTA-16 trial for acute coronary syndrome was halted due to a lack of efficacy and an increased risk of myocardial infarction, highlighting the therapeutic challenges and safety concerns of broad sPLA2 inhibition. More recently, novel therapeutic strategies have emerged, such as kesonotide, a cyclic peptide designed to selectively block the non-catalytic, protein-protein interactions of PLA2G2A with vimentin and EGFR, offering a promising approach for treating advanced solid tumors like prostate cancer. Additionally, circulating levels of PLA2G2A serve as valuable biomarkers for monitoring systemic inflammation, cardiovascular risk, and disease prognosis.
Inhibition of the active site to block phospholipid hydrolysis and eicosanoid precursor release, or selective inhibition of non-catalytic protein-protein interactions (such as with EGFR and vimentin) to block downstream pro-inflammatory and proliferative signaling.
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Phospholipase A2 group IIA (PLA2G2A).